Home › Treatment Guides › Mounjaro Before and After UK
Mounjaro Before and After UK: Real Results, Clinical Evidence & Month-by-Month Timeline 2026
Start Your Mounjaro Journey at Slinic — From £139, Delivered Tomorrow
GPhC No. 1033729 · NHS-contracted · SCOPE Obesity Accredited · Fixed 2026 prices · Free monthly check-ins · Next-day cold-chain to every UK postcode
- ✅ Mounjaro 2.5mg £139 · 5mg £165 · 7.5mg £225 · 10mg £255 · 12.5mg £275 · 15mg £285
- ✅ Free starter pack (needles + sharps bin + injection guide) with every 2.5mg first order
- ✅ Free monthly clinical check-ins throughout your treatment · No subscription · No minimum term
- ✅ Authorised Eli Lilly UK supply chain only · Next-day tracked cold-chain delivery
You have probably scrolled past Mounjaro before and after photos at midnight. Some of them look extraordinary. But photos leave out the context that actually matters — the starting weight, the timeframe, what else changed, whether the dose had escalated. This guide gives you the clinical reality instead: what the trial evidence shows, what actually happens month by month, what influences results, and what UK patients prescribed Mounjaro at Slinic most commonly experience.
This is not a sales pitch. It is the most accurate UK guide to Mounjaro before and after results available from any prescriber — because setting realistic expectations is what makes the difference between patients who succeed and patients who give up at week 6 expecting a miracle that should take months.
What the Clinical Trials Actually Show
The evidence for Mounjaro is unusually robust — the SURMOUNT programme is one of the largest weight management trial programmes ever conducted, and its results have been independently replicated. Here is what the data actually says:
| Trial | Dose | Duration | Average weight loss | Key finding |
|---|---|---|---|---|
| SURMOUNT-1 (NEJM 2022) | 5mg | 72 weeks | 15.0% | Even the lowest therapeutic dose outperformed all previously approved weight loss medications |
| SURMOUNT-1 (NEJM 2022) | 10mg | 72 weeks | 19.5% | Approximately 1 in 3 patients achieved 25%+ weight loss |
| SURMOUNT-1 (NEJM 2022) | 15mg | 72 weeks | 22.5% | More than half of patients achieved ≥20% weight loss — unprecedented for any approved medication |
| SURMOUNT-5 (NEJM 2025) | 15mg vs Wegovy 2.4mg | 72 weeks | 20.2% vs 13.7% | Definitive head-to-head — Mounjaro outperforms Wegovy by 47% on weight loss |
| SURMOUNT-4 (NEJM 2024) | Continuation vs stop | 88 weeks | Continued: further loss. Stopped: 14% regain | Ongoing treatment essential for maintained results — stopping leads to predictable regain |
Mounjaro Before and After — Month by Month: The Honest Timeline
This is the section most before-and-after content skips. Dramatic transformations on social media almost always show 6–12+ months of results, not 4 weeks. Here is what actually happens at each stage for the majority of UK patients.
| Stage | Typical dose | Clinical changes | What most patients experience | Average weight loss from start |
|---|---|---|---|---|
| Weeks 1–4 | 2.5mg | GLP-1 and GIP receptors begin activating. Gastric emptying slows. Appetite signalling begins changing. | Appetite begins dipping within 7–10 days. Food noise quietening noticeably. Nausea possible — peaks days 2–3, fades by day 5. Portions feel larger than before. | 1–3kg (primarily appetite reduction and water shifts) |
| Weeks 4–8 | 5mg | First dose escalation. Therapeutic effect increasing. Sustained appetite suppression establishing. | Genuine hunger reduction. Weight moving consistently downward. Side effects usually easing as GI system adapts. Energy often improving. Clothes beginning to feel different. | 3–6kg cumulative |
| Months 2–3 | 7.5mg | Second escalation. Fat oxidation accelerating. Metabolic improvements beginning — blood pressure, HbA1c, lipids. | Visible physical changes becoming apparent to others. Face, waist, and upper body changing noticeably. Satiety lasts longer between meals. Strong reduction in food cravings. | 6–10kg cumulative |
| Months 3–6 | 10mg–12.5mg | Peak weight loss velocity phase. GIP-mediated fat cell metabolism at full effect. Waist circumference reducing significantly. | Most dramatic before-and-after change period. Clothes sizes often dropping. Significant non-scale improvements: joint pain, sleep quality, mobility, blood sugar, blood pressure. Appetite deeply suppressed. | 10–18kg cumulative |
| Months 6–12 | 12.5mg–15mg | Approaching plateau. Rate of loss slowing naturally as body adapts. Metabolic benefits consolidating. | Weight loss continuing but more gradually. Focus shifting to maintenance habits. Continued metabolic improvements. Many patients achieve personal goal weight during this phase. | 15–22%+ of starting body weight |
| 12+ months (maintenance) | 5mg–15mg depending on individual | Long-term weight management phase. Ongoing GLP-1/GIP receptor stimulation preventing regain. | Weight stabilising at new lower set point. SURMOUNT-4 data: patients who continue treatment maintain loss; those who stop regain ~14% within 88 weeks. Maintenance dose (often 5–7.5mg) considered. | Maintained — regain prevented |
The Changes That Don’t Show Up in Photos
Before-and-after galleries on social media are inevitably visual — they show bodies. But the changes UK patients on Mounjaro most consistently report as most meaningful are not always visible in a photo:
Food noise — the most underreported before-and-after
Food noise is the constant mental preoccupation with food — thinking about the next meal, struggling past the biscuit tin, feeling driven to eat even when not physically hungry. It is a hallmark of obesity as a biological condition, not a character flaw. Mounjaro’s effect on GLP-1 and GIP receptors quietens food noise profoundly — often within the first 2 weeks, even at 2.5mg. Most patients describe this as one of the most significant changes they experience. It is not visible in a photo. It is life-changing.
Joint pain reduction
Every 1kg of weight lost removes approximately 4kg of pressure from the knee joints during daily activity. For patients with obesity-related osteoarthritis — common among Mounjaro patients — the reduction in joint pain during treatment is often more immediately impactful than any visual change. Many patients report being able to walk distances, climb stairs, and exercise in ways that were not possible before treatment.
Sleep quality
Excess weight is strongly associated with obstructive sleep apnoea and poor sleep quality. Weight loss on Mounjaro frequently improves sleep significantly — often within the first few months. Patients report waking more rested, snoring less, and no longer requiring CPAP machines in some cases. Better sleep amplifies energy, mood, and adherence to lifestyle changes.
Blood sugar, blood pressure, and lipids
The metabolic benefits of Mounjaro extend beyond weight. In SURPASS-2 (NEJM 2021), Mounjaro reduced HbA1c by an average of 2.58 percentage points at 15mg — the strongest glucose-lowering effect of any approved treatment. Blood pressure reductions and lipid improvements are also documented. These benefits are clinically significant but completely invisible in a before-and-after photo.
What Affects How Much Weight You Lose — The Six Factors
| Factor | What it means in practice | What you can do |
|---|---|---|
| Starting dose and escalation rate | 2.5mg is not a therapeutic dose — it is an adjustment dose. Meaningful weight loss accelerates as dose escalates. Patients who tolerate faster escalation reach therapeutic doses sooner. | Manage side effects well during escalation to avoid dose holds. Tell your Slinic prescriber if you’re tolerating a dose well before the 4-week review. |
| Dietary protein intake | High protein intake (1.2–1.6g/kg/day) amplifies Mounjaro’s satiety effect and preserves muscle mass during weight loss. Patients with high protein intake consistently show stronger weight loss in real-world data. | Prioritise protein at every meal. Chicken, fish, eggs, Greek yoghurt, legumes. Don’t let Mounjaro’s appetite suppression cause you to under-eat protein. |
| Physical activity | Resistance exercise preserves muscle mass and increases metabolic rate during weight loss — both of which accelerate fat loss results. Cardio adds caloric expenditure. | Aim for 2+ resistance sessions per week alongside any cardio. Even walking 8,000+ steps daily shows measurable benefit in clinical data. |
| Caloric compensation | Some patients unconsciously eat more calorie-dense foods as appetite reduces total volume — neutralising the caloric deficit. This is the most common cause of unexpectedly slow results. | Focus on food quality, not just quantity. Mounjaro reduces volume — ensure what you do eat is not high in processed fats and sugars. |
| Starting BMI | Patients with higher starting BMIs typically lose more absolute weight but similar percentages. Patients with BMI 27–30 may see somewhat lower percentage losses than those with BMI 40+. | Understand that percentage loss is the meaningful clinical metric — not kg. A 20% loss is equally significant whether you start at 80kg or 130kg. |
| Individual metabolic response | Some patients are genetically higher or lower responders to tirzepatide’s GLP-1 and GIP receptor agonism. This is not avoidable — it reflects biology, not effort. | If you are a lower responder, optimise all other factors before concluding the medication isn’t working. Discuss dose optimisation with your prescriber at your monthly check-in. |
Mounjaro vs Wegovy — The Before and After Comparison
The definitive answer came in 2025 with the SURMOUNT-5 head-to-head trial — the first ever direct comparison between Mounjaro and Wegovy in weight management.
| Metric | Mounjaro 15mg | Wegovy 2.4mg | Mounjaro advantage |
|---|---|---|---|
| Average weight loss at 72 weeks | 20.2% | 13.7% | +47% greater loss |
| Patients achieving ≥20% loss | Majority | Minority | Significantly more patients reaching the 20% threshold |
| HbA1c reduction (T2D patients) | 2.58pp at 15mg (SURPASS-2) | ~1.6pp at 2.4mg | Stronger glycaemic control |
| Waist circumference reduction | Greater | Less | More visceral fat reduction |
| Blood pressure reduction | Greater | Less | Stronger cardiovascular metabolic benefit |
| Mechanism | Dual GIP + GLP-1 receptor agonism | GLP-1 receptor agonism only | Two pathways vs one — the reason for the difference |
| Slinic price from | £139/month (2.5mg) | £99.99/month (0.25mg) | Mounjaro available from £139 — transparent fixed pricing |
Start Your Mounjaro Journey at Slinic
Free 2-minute assessment · Named prescriber review · Next-day delivery · GPhC No. 1033729 · Mounjaro from £139
What to Expect at 1 Month, 3 Months, 6 Months, and 12 Months
Before and after at 1 month
At 1 month, you are on 2.5mg. This is the adjustment dose — not the therapeutic dose. Most patients have lost 1–3kg, primarily from eating less due to beginning appetite suppression and some water weight shift. The most significant change at 1 month is internal: quieter food noise, smaller portion sizes, and noticeably less compulsive thinking about food. Visible physical changes at 1 month are minimal for most patients. This is normal — not a sign the medication isn’t working.
Before and after at 3 months
At 3 months, most patients are on 7.5mg or 10mg. Average cumulative weight loss is 8–12% of starting body weight. This is the stage where visible changes become apparent to others — face slimming, waist reduction, clothes fitting differently. Many patients are moving one dress or trouser size down. Non-scale improvements are significant: better energy, reduced joint pain, improved sleep, measurably better blood sugar and blood pressure in patients with metabolic conditions. This is often when the most sustained motivation sets in — patients feel and see the difference clearly.
Before and after at 6 months
At 6 months, most patients are on 10mg–15mg. Average cumulative loss is 14–19% of starting body weight. This is when the most dramatic visual transformations occur. Multiple clothing sizes lost, significant changes in face and body shape, and in many cases, the resolution or significant improvement of weight-related conditions. Many patients with T2D see HbA1c improvements that reduce or eliminate the need for other diabetes medication. Blood pressure often normalising. Physical activity capacity significantly improved.
Before and after at 12 months
At 12 months, patients on maximum tolerated dose have typically achieved 18–22%+ of body weight lost. This represents 18–22kg for someone starting at 100kg, and up to 26–30kg for someone starting at 130kg. The visual transformation at 12 months is typically dramatic. Metabolic health is transformed. The clinical question at 12 months is maintenance — whether to continue at the current dose, step down to a lower maintenance dose, or plan a supervised stop.
What If Your Results Are Slower Than Expected?
If your weight loss is slower than the averages above, there are six causes to investigate — all of them addressable:
- You are still on 2.5mg. This is an adjustment dose, not a therapeutic dose. Progress accelerates significantly from 5mg upward. If you have been on 2.5mg longer than 4 weeks without tolerability issues, discuss escalating with your Slinic prescriber.
- Caloric compensation. As Mounjaro reduces appetite and meal volume, some patients unconsciously replace volume with caloric density — eating smaller amounts of high-calorie foods. Net caloric intake barely changes. Track what you eat for 1 week honestly to check for this pattern.
- Insufficient protein. Low protein intake reduces the satiety amplification Mounjaro provides and causes muscle loss rather than fat loss during the caloric deficit. Aim for 1.2–1.6g of protein per kg of bodyweight daily.
- Sedentary lifestyle. Mounjaro creates a caloric deficit through appetite — exercise multiplies this deficit and preserves muscle. Patients who are sedentary lose weight more slowly and lose more muscle alongside fat.
- Dose not yet at therapeutic level. Full clinical efficacy builds as dose escalates. If you have only reached 5mg, results at 10mg or 15mg will be significantly stronger.
- Individual metabolic variation. Some patients are lower responders to tirzepatide. This is a biological reality. If all other factors are optimised and results remain below 5% at 3 months on a therapeutic dose, discuss with your Slinic prescriber — alternative treatment options exist.
Setting Realistic Expectations — What Slinic Tells Every New Patient
1. The first 4 weeks are about adaptation, not transformation. Do not judge the medication by month 1 results.
2. The scale is not the only measure of progress. Food noise reduction, joint pain relief, better sleep, and improved energy are all real and significant before-and-after changes.
3. The 2.5mg dose is not where results happen. Be patient through the early titration. Results compound with every dose escalation.
4. The best before-and-after is the one that lasts. Patients who combine Mounjaro with sustainable dietary habits — especially high protein — maintain more of their results long-term than those who rely on the medication alone.
Frequently Asked Questions
How much weight can I realistically expect to lose on Mounjaro in the UK?
Clinical trial data from SURMOUNT-1 (2,539 patients, 72 weeks) shows average weight loss of 15% at 5mg, 19.5% at 10mg, and 22.5% at 15mg. In SURMOUNT-5 (2025), Mounjaro outperformed Wegovy at 20.2% vs 13.7%. Real-world UK results broadly match these figures. Your personal result depends on your starting weight, the dose you reach, your dietary approach, and individual metabolic variation. For someone starting at 100kg, a 20% loss represents 20kg over approximately 12 months at maximum dose.
When will I see visible before-and-after changes on Mounjaro?
Most patients notice the first visible physical changes — face slimming, slight waist reduction — at weeks 4–6. Changes become clearly apparent to others at around month 3. The most dramatic before-and-after visual transformation typically occurs between months 3 and 9, as patients escalate through 7.5mg, 10mg, and 12.5mg. Social media before-and-after photos that look dramatic are almost always showing 6+ months of results — often at maximum dose.
What is a realistic Mounjaro before and after at 3 months?
At 3 months, most patients are on 7.5mg–10mg and have lost 8–12% of starting body weight — approximately 8–12kg for someone starting at 100kg. Visible changes are apparent: face, waist, clothing size. Non-scale changes are significant: reduced food noise, better energy, often improved sleep and reduced joint pain. Blood pressure and HbA1c improvements are measurable in patients with metabolic conditions.
Does Mounjaro work better than Wegovy for before-and-after results?
Yes — by a significant margin, according to the 2025 SURMOUNT-5 trial, the first ever head-to-head comparison. Mounjaro achieved 20.2% average weight loss versus 13.7% for Wegovy over 72 weeks — 47% greater loss. The difference is attributed to Mounjaro’s dual GIP and GLP-1 receptor mechanism. Both are effective weight loss medicines, but Mounjaro consistently produces stronger results in every trial where they have been compared.
What if I’m not losing weight on Mounjaro?
If your results are slower than expected, check these factors: Are you still on 2.5mg (not therapeutic)? Are you compensating calories with denser foods? Is protein intake adequate (1.2–1.6g/kg/day)? Are you sedentary? Have you escalated to a meaningful dose? Raise slow progress at your monthly Slinic check-in. Your prescriber reviews your dose, dietary approach, and clinical response — and can adjust your treatment plan. Changing the dose or adding dietary guidance resolves most cases of unexpectedly slow progress.
How do I start Mounjaro at Slinic?
Complete the free 2-minute eligibility assessment at slinic.co.uk/consultation. A named Slinic prescriber reviews your assessment same working day. If approved, Mounjaro is dispatched within 24 hours — next-day cold-chain tracked delivery to your UK address. First order at 2.5mg is £139, with a free starter pack including needles, sharps bin, and injection guide. No subscription, no minimum term, fixed 2026 prices throughout.
Clinical Trial References
- SURMOUNT-1 — Jastreboff AM et al. Tirzepatide Once Weekly for Obesity. NEJM 2022
- SURMOUNT-4 — Aronne LJ et al. Continued Tirzepatide for Weight Maintenance. NEJM 2024
- SURMOUNT-5 — Garvey WT et al. Tirzepatide vs Semaglutide. NEJM 2025
- SURPASS-2 — Frias JP et al. Tirzepatide vs Semaglutide in T2D. NEJM 2021
- NICE TA1026 — Tirzepatide for managing overweight and obesity (June 2025)
Related Treatment Guides
Mounjaro Dosing Schedule UK 2026Full titration guide — ranked #1 UK
Mounjaro Side Effects UK 2026Clinical management — ranked #1 UK
Mounjaro Eligibility UK 2026NHS + private criteria, ethnic BMI, all cohorts
Restarting Mounjaro After a BreakCorrect dose by break length
Mounjaro vs Wegovy UK 2026SURMOUNT-5 head-to-head results
Begin Your Mounjaro Transformation at Slinic — Every Dose in Stock
GPhC No. 1033729 · NHS-contracted · SCOPE Obesity Accredited · LegitScript Certified · Fixed 2026 prices · No subscription
- ✅ Mounjaro 2.5mg £139 → 15mg £285 · all doses dispatched within 24 hours
- ✅ Free starter pack (needles + sharps bin) · Free monthly clinical check-ins throughout
- ✅ Named prescriber review · Not automated · Authorised Eli Lilly UK supply chain
- ✅ No subscription · No minimum term · Next-day cold-chain tracked delivery to every UK postcode
